Table 1.
Classification of patients treated with sublingual immunotherapy (SLIT) based on ΔMSS. Patients were stratified based on ΔMSS to identify patients who had a better clinical response as compared to those with a poor response to SLIT. ΔMSS-12: evaluation after 12 months of SLIT treatment; ΔMSS-24: evaluation after 24 months of SLIT treatment.
| ΔMSS | ΔMSS-12 (N, %) |
ΔMSS-24 (N, %) |
|
|---|---|---|---|
| Very high symptom improvement | ΔMSS ≥ 75% | 39 (39.80%) |
41 (41.84%) |
| High symptom improvement | 50% ≤ ΔMSS < 75% | 37 (37.76%) |
41 (41.84%) |
| Mild symptom improvement | 25% ≤ ΔMSS < 50% | 10 (10.20%) |
14 (14.29%) |
| Low symptom improvement | ΔMSS < 25% | 12 (12.24%) |
2 (2.04%) |
| Total | 98 (100.00%) |
98 (100.00%) |